These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12839095)

  • 1. The cellular and clinical parameters of anabolic therapy for osteoporosis.
    Rosen CJ
    Crit Rev Eukaryot Gene Expr; 2003; 13(1):25-38. PubMed ID: 12839095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy-associated plasma protein-A modulates the anabolic effects of parathyroid hormone in mouse bone.
    Clifton KB; Conover CA
    Bone; 2015 Dec; 81():413-416. PubMed ID: 26297833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New anabolic therapies in osteoporosis.
    Rubin MR; Bilezikian JP
    Curr Opin Rheumatol; 2002 Jul; 14(4):433-40. PubMed ID: 12118181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anabolic agents for treating postmenopausal osteoporosis.
    Meunier PJ
    Joint Bone Spine; 2001 Dec; 68(6):576-81. PubMed ID: 11809001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.
    Aslan D; Andersen MD; Gede LB; de Franca TK; Jørgensen SR; Schwarz P; Jørgensen NR
    Scand J Clin Lab Invest; 2012 Feb; 72(1):14-22. PubMed ID: 22085136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New mechanisms and targets in the treatment of bone fragility.
    Martin TJ; Seeman E
    Clin Sci (Lond); 2007 Jan; 112(2):77-91. PubMed ID: 17155930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis.
    Whitfield JF; Morley P; Willick GE
    Treat Endocrinol; 2002; 1(3):175-90. PubMed ID: 15799210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.
    Horwitz MJ; Tedesco MB; Gundberg C; Garcia-Ocana A; Stewart AF
    J Clin Endocrinol Metab; 2003 Feb; 88(2):569-75. PubMed ID: 12574182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women.
    Adami S
    Curr Med Res Opin; 2008 Nov; 24(11):3259-74. PubMed ID: 18940041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New anabolic therapies in osteoporosis.
    Rubin MR; Bilezikian JP
    Endocrinol Metab Clin North Am; 2003 Mar; 32(1):285-307. PubMed ID: 12699304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconstructing the skeleton with intermittent parathyroid hormone.
    Seeman E; Delmas PD
    Trends Endocrinol Metab; 2001 Sep; 12(7):281-3. PubMed ID: 11504661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?
    Delmas PD; Vergnaud P; Arlot ME; Pastoureau P; Meunier PJ; Nilssen MH
    Bone; 1995 Jun; 16(6):603-10. PubMed ID: 7669436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging anabolic treatments for osteoporosis.
    Rosen CJ; Rackoff PJ
    Rheum Dis Clin North Am; 2001 Feb; 27(1):215-33, viii. PubMed ID: 11285997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miscellaneous and experimental agents.
    Reginster JY
    Am J Med Sci; 1997 Jan; 313(1):33-40. PubMed ID: 9001164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What's new with PTH in osteoporosis: where are we and where are we headed?
    Rosen CJ
    Trends Endocrinol Metab; 2004 Jul; 15(5):229-33. PubMed ID: 15223053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
    Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
    Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
    Compston JE
    Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
    Wang L; Quarles LD; Spurney RF
    J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.